REGULATORY:FDA Approves Ruconest to Treat Rare Genetic Disease
Salix and Pharming’s new biologic is produced in the milk of transgenic rabbits.
The U.S. Food and Drug Administration has approved Ruconest, the first recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, a rare genetic disease. The drug, developed by Dutch biotech Pharming, is already marketed in the European Union. Read More